AEMD READ THE FULL AEMD RESEARCH REPORT Patient enrollments begin for AEMD’s basket oncology trial Aethlon Medical (NASDAQ:AEMD) announced FY 2Q results and provided a business update yesterday. The ...

Keytruda alone generated $25 billion last year across multiple indications. That still left room for rivals to generate ...

However, BMS’ setback is further good news for MSD’s Keytruda, which now looks increasingly likely to become the dominant player in NSCLC globally, after Opdivo failed to show efficacy as a ...

The positive readout from the CheckMate-76K study means that Opdivo (nivolumab) has a chance to draw level again with Merck & Co's rival cancer immunotherapy Keytruda (pembrolizumab), which was ...

Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

section above. Like Keytruda, Opdivo is a programmed death receptor-1 (PD-1) blocking antibody (type of immune system protein). These drugs help your immune system detect cancer cells in your body ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

JMP notes despite the incredible clinical and commercial success of Merck & Co. Inc’s (NYSE:MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first ...